ArticleScientific reports2026
C-reactive protein-triglyceride glucose index as a predictor of heart failure risk in adults with MASLD: a prospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Heart failure (HF) is a major complication of metabolic dysfunction-associated steatotic liver disease (MASLD). The C-reactive protein-triglyceride glucose index (CTI), which reflects systemic inflammation and insulin resistance, is linked to cardiovascular outcomes, but its predictive value for HF in MASLD patients remains unclear. We aimed to evaluate the baseline and cumulative CTI (CumCTI) in relation to incident HF and explore blood pressure as a potential mediator. We included 26,499 participants with MASLD from the Kailuan Study. The baseline and CumCTI values were calculated and examined for associations with HF via Cox regression. Restricted cubic splines were used to assess dose‒response patterns. Predictive performance was evaluated using C-index, reclassification metrics, time-dependent ROC curves, and calibration analyses. During a median follow-up of 16.0 years, 1,158 HF events occurred. A higher CTI was independently associated with increased HF risk (HR for Q4 vs. Q1: 1.78; 95% CI: 1.48-2.11; P < 0.001), with each 1-SD increase corresponding to a 27% greater risk (HR 1.27; 95% CI: 1.19-1.35). CumCTI showed stronger associations with HF and modestly improved model discrimination and reclassification compared with conventional risk factors. Time-dependent ROC analyses showed slight increases in AUC at 5 and 10 years after adding CumCTI (0.782 to 0.783 and 0.763 to 0.767, respectively), with good calibration between predicted and observed risks. Mediation analysis indicated that systolic and diastolic blood pressure explained only a small proportion of the CTI-HF association. Associations were stronger for CumCTI in participants aged < 60 years. These findings suggest that a higher CTI, especially cumulative exposure, is independently associated with HF risk in MASLD and may provide complementary information for cardiovascular risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.